Media coverage
7Media coverage
Title The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients Media name/outlet BioSpace Country United States Date 5/9/17 Persons Angela Alistar Title The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer Media name/outlet 4 Traders Country United States Date 5/9/17 Persons Angela Alistar Title The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer Media name/outlet PharmiWeb Country United Kingdom Date 5/9/17 Persons Angela Alistar Title The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer Media name/outlet GlobeNewswire Country United States Date 5/9/17 Persons Angela Alistar Title The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients Media name/outlet Daily Times Leader Country United States Date 5/9/17 Persons Angela Alistar Title The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer Media name/outlet PR Distribution Country Poland Date 5/9/17 Persons Angela Alistar Title The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreati Media name/outlet BizWire Express Country India Date 5/9/17 Persons Angela Alistar